Table 3 A list of few vaccines that completed clinical trial phase 3
From: SARS-CoV-2 infection: a global outbreak and its implication on public health
Vaccine name | Research name | Vaccine type | Manufacturer | Country of origin | Side effects | Efficacy | References |
|---|---|---|---|---|---|---|---|
Comirnaty | BNT162b2 | 3 LNP-mRNAs | Pfizer, BioNTech, Fosun Pharma | Multinational | Fatigue, headache, myalgia, chills, arthralgia | 95% | |
Moderna COVID-19 vaccine | Mrna-1273 | LNP-encapsulated mRNA | Moderna, BARDA, NIAID | US | Tiredness, headache, muscle pain, chills, fever, nausea | 94% | |
AstraZeneca also known as Vaxzevria and Covishield | AZD1222 | Non-replicating viral vector ChAdOx1-S | BARDA, OWS | UK | Tiredness, headache, muscle pain, chills, fever, nausea | 70% | |
Sputnik V | Â | Non-replicating viral vector | Gamaleya research institute, Acellena contract drug research and development | Russia | Breathing difficulties, convulsions, swelling muscle weakness, high BP, headaches, dizziness | 92% | |
Janssen | JNJ-78436735; Ad26.COV2.S | Non-replicating viral vector | Janssen vaccines (Johnson & Johnson) | The Netherlands, US | Headache, fever, fatigue, muscle aches, nausea, irritation, redness | 68% | |
CoronaVac | Â | Inactivated vaccine (formalin with alum adjuvant) | Sinovac | China | Rash, headache, muscle pain, fever, nausea, vomiting, injection site pain, fatigue | 78% | |
Sinopharm | BBIBP-CorV | Inactivated vaccine | Beijing institute of biological products; China national pharmaceutical group (Sinopharm) | China | Lethargy, drowsiness, difficulty sleeping, sneezing, nasopharyngitis, nasal congestion | 86% | |
EpiVacCorona |  | Peptide vaccine | Federal budgetary research institution state research center of virology and biotechnology | Russia | – | – | Jeff Craven (2021) |
Convidicea | Ad5-nCoV | Recombinant vaccine (adenovirus type 5 vector) | CanSino Biologics | China | Fever, pain, swelling, sensitivity, fatigue, pain in muscles, joints and heads | 66% | |
Covaxin | BBV152 | Inactivated vaccine | Bharat Biotech, ICMR; Ocugen | India | Pain, headache, fatigue, fever, body ache, abdominal pain, nausea, tremor, sweating, cold, cough | 78% | |
WIBP-CorV | Â | Inactivated vaccine | Wuhan institute of biological products; China national pharmaceutical group (Sinopharm) | China | Rash, headache, muscle pain, fever, nausea, vomiting, injection site pain | 72,51% | Jeff Craven (2021) |
CoviVac |  | Inactivated vaccine | Chumakov Federal scientific center for research and development of immune and biological products | Russia | – | – | Jeff Craven (2021) |
| Â | ZF2001 | Recombinant vaccine | Anhui Zhifei Longcom biopharmaceutical institute of microbiology of the Chinese academy of sciences | China, Uzbekistan | Injection pain, redness, swelling | - | Jeff Craven (2021) |
QazVac (QazCovid-in) |  | Inactivated vaccine | Research institute for biological safety problems | Kazakhstan | – | – | Jeff Craven (2021) |
Novavax | NVX-Cov2373 | Recombinant nanoparticle | Biofabri in Spain, FUJIFILM Diosynth Biotechnologies (FDB) in both North Carolina and Texas in the US, FDB in the UK, SIIPL in India, SK Bioscience in the Republic of Korea, Takeda Pharmaceutical Company Limited in Japan | UK & South Africa | Rash, headache, muscle pain, fever, nausea, vomiting, injection site pain | 89.3% | Novavax (2021) |